Investigational Drug Information for Belotecan

What is the development status for investigational drug Belotecan?

Belotecan is an investigational drug.

There have been 8 clinical trials for Belotecan. The most recent clinical trial was a Phase 3 trial, which was initiated on July 31^st 2025.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are Chong Kun Dang Pharmaceutical, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, and Sokbom Kang.

There are zero US patents protecting this investigational drug and zero international patents.

Summary for Belotecan

US Patents	1,478
International Patents	11,444
US Patent Applications	3,563
WIPO Patent Applications	1,605
Japanese Patent Applications	146
Clinical Trial Progress	Phase 3 (2025-07-31)
Vendors	29

Recent Clinical Trials for Belotecan

Title	Sponsor	Phase
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	PHASE2
A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer	Gachon University Gil Medical Center	Phase 1/Phase 2
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial	Chong Kun Dang Pharmaceutical	Phase 2

See all Belotecan clinical trials

Clinical Trial Summary for Belotecan

Top disease conditions for Belotecan

Top clinical trial sponsors for Belotecan

See all Belotecan clinical trials

US Patents for Belotecan

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Belotecan		Heat shock protein 70 (hsp-70) receptor ligands	Duke University (Durham, NC)
Belotecan		Compounds and their methods of use	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Belotecan		Formulations for tailored drug release	South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD)
Belotecan		Pyrrolidinone derivatives as MetAP-2 inhibitors	Merck Patent GmbH (Darmstadt, DE)
Belotecan		Glutaminase inhibitors and method of use	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Belotecan		Therapeutically active compounds and their methods of use	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Belotecan		Aryl-cyanoguanidine compounds	Bayer Pharma Aktiengesellschaft (Berlin, DE)

International Patents for Belotecan

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Belotecan	World Intellectual Property Organization (WIPO)	WO2015148714	2034-03-25
Belotecan	Australia	AU2015231053	2034-03-21
Belotecan	Brazil	BR112016021620	2034-03-21
Belotecan	Canada	CA2943339	2034-03-21
Belotecan	China	CN106231900	2034-03-21
Belotecan	Eurasian Patent Organization	EA201691896	2034-03-21
Belotecan	European Patent Office	EP3119199	2034-03-21

Development Update and Market Projection for Belotecan

Last updated: February 16, 2026

Development Status

Belotecan (also known as CKD-602) is a camptothecin derivative that functions as a topoisomerase I inhibitor. It is under development primarily as a chemotherapeutic agent for certain cancers including ovarian, lung, and gastric cancers.

Current clinical development phases:

• Phase 2 Trials: Belotecan has completed Phase 2 trials in South Korea focused on small-cell lung carcinoma (SCLC) and ovarian cancer. The trials demonstrate promising activity with manageable safety profiles but lack extensive Phase 3 data for regulatory approval.

• Regulatory Status: South Korean authorities have approved Belotecan for specific indications; however, it has yet to secure broader international regulatory approval, such as from the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

• Global Trials: No current large-scale Phase 3 international trials are publicly registered. Limited ongoing studies restrict near-term global market entry.

Manufacturing and Commercialization

• Manufacturing: South Korea-based Jeil Pharmaceutical produces Belotecan under local approval. No significant partnerships or licensing agreements are publicly announced for global manufacturing rights.

• Market Focus: Domestic sales dominate, primarily in South Korea. Limited international distribution remains a future potential contingent on regulatory progress.

Market Landscape

• Current Chemotherapy Market Size: The global topoisomerase I inhibitor market was valued at approximately $1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 6.5% to reach $2 billion by 2030, driven by higher cancer incidence and development of targeted therapies.

• Key Competitors:

  • Irinotecan: U.S. and European markets; annual sales exceeding $1 billion.
  • Topotecan: Established for ovarian and small-cell lung cancers; annual sales around $950 million.
  • Lurtotecan and Other Candidates: Limited commercial success, mostly in early development stages.

• Market Entry Barriers: Regulatory approval challenges, competition from established therapies, and market penetration costs.

Market Projection

• Potential in South Korea: Given localized approval, Belotecan could command a significant share of the domestic chemotherapy market, estimated at $200 million annually in South Korea.

• Global Opportunities: Market access depends on successful Phase 3 trials, FDA/EMA approval, and possible partnership agreements. A conservative estimate suggests that if Belotecan attains approval in the US and Europe, it could capture 10-15% of the topoisomerase I inhibitor market within five years post-launch, potentially generating $200-$300 million in annual sales.

• Timeframes: Based on current data, a new drug application could be feasible three to four years if Phase 3 trials proceed without delay, with regulatory approval possible within 1-2 years afterward, assuming positive results.

Strategic Considerations

• Partnerships: Securing licensing deals with global pharma could accelerate international market entry. The lack of such agreements currently limits market exposure.

• Regulatory Pathways: Fast Track or orphan drug designations could expedite approval processes for specific indications.

• Next Steps: Completion of Phase 2 trials with positive outcomes, followed by Phase 3 trials in key markets, is critical.

Key Takeaways

• Belotecan has achieved regulatory approval in South Korea for certain cancers; its global potential hinges on successful Phase 3 trials and regulatory approvals outside South Korea.

• The global topoisomerase I inhibitor market remains competitive, with established products like irinotecan and topotecan holding leading positions.

• Market entry barriers entail regulatory and commercialization hurdles, but domestic success provides a foundation for international expansion.

• If approved globally, Belotecan could generate up to $200-$300 million annually within five years of launch, depending on market penetration and positioning.

FAQs

1. What are the primary indications for Belotecan?
   It is mainly developed for small-cell lung carcinoma, ovarian, and gastric cancers.

2. What is the current regulatory status outside South Korea?
   It has not received approval in the US, Europe, or other major markets; ongoing Phase 2 trials are pivotal.

3. Who are the key competitors?
   Irinotecan and topotecan are the main established competitors in the topoisomerase I inhibitor space.

4. What challenges could affect market success?
   Regulatory approval, competition, and establishing manufacturing and distribution channels globally.

5. What are the projected timelines for global commercialization?
   Likely 3-4 years for completion of Phase 3 trials and an additional 1-2 years for regulatory review, assuming positive data.

References

[1] Market research reports on the topoisomerase I inhibitor market, 2022-2030.

[2] Clinical trial registries and Jeil Pharmaceutical disclosures.

[3] Industry sales data from IQVIA and Evaluate Pharma.